Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

narcolepsy

Are we ready for an Alzheimer’s disease modifying treatment

Millions of people across the globe have Alzheimer’s disease and currently, there is no cure. But if a new therapy entered the market today, would healthcare systems be ready for...

Blue Latitude Health

- PMLiVE

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Latest blow in string of failures for BACE inhibitor category

- PMLiVE

Intec sounds a sad note as Accordion Parkinson’s trial fails

Intec’s lifeline now is Novartis partnership

- PMLiVE

AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy

Novel chimeric peptide ready to start clinical trials

- PMLiVE

Bicycles Therapeutics enters dementia discovery with venture capital fund

Ambitious UK biotech expands research scope

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

- PMLiVE

GW Pharma’s cannabis-based medicine to be tested in dementia

Trial will be funded by Alzheimer’s Research UK

- PMLiVE

Another amyloid bust as Roche pulls crenezumab trials

Undermines amyloid hypothesis hopes. including Biogen candidate

- PMLiVE

Researchers reverse Alzheimer’s memory loss in mice

Epigenetics opens up new potential drug targets

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

Healthcare leaders in the European Union should begin preparing for a breakthrough now

- PMLiVE

Theranexus takes Alzheimer’s drug combo into clinic

150-subject phase 1b trial to start at eight centres in France

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links